Company news
Wellbeing Digital Sciences Inc. (OTC:KONEF) news
Wellbeing Digital Sciences Inc. news releases on 6ix. Latest, Feb 16, 2023: Wellbeing Provides Bi-Weekly Default Status Report
Press releases & updates
Wellbeing Provides Bi-Weekly Default Status Report
February 16, 2023
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.
February 15, 2023
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial
February 14, 2023
Wellbeing Digital Announces Change of Auditor
January 18, 2023
Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial
December 22, 2022
Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada
December 8, 2022
Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response
December 6, 2022
Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial
November 30, 2022
Wellbeing Subsidiary Mindscape Treats its 1,000th Patient
November 29, 2022
Wellbeing Digital Announces the Appointment of Mohammad Sharifi to Board of Directors
November 22, 2022
Wellbeing Digital Announces Resignation of Directors
November 18, 2022
Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial
November 17, 2022
Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers
November 14, 2022
Wellbeing Digital Subsidiary KGK to Participate in Microdose Wonderland Miami Conference
November 2, 2022
Wellbeing Announces Definitive Agreement to Divest IRP Health
October 27, 2022
Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference
October 25, 2022
Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference
October 13, 2022
Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics
October 11, 2022
Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial
October 6, 2022
Wellbeing Digital Signs LOI Manage Additional Clinics
October 4, 2022
Wellbeing Digital to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics
September 29, 2022
Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future
September 26, 2022
Wellbeing Digital to Participate in the Microdose Psychedelic Capital Conference
September 23, 2022
Wellbeing Digital Reports Financial Results for the Fourth Fiscal Quarter
September 15, 2022
Wellbeing’ CEO Joins Benzinga’s Psychedelic Advisory Board
August 30, 2022
Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo® Branded Ingredient from FDA
August 25, 2022
Wellbeing Subsidiary IRP Health Toronto Location Approved by Veterans Affairs Canada for Its Reactivation Program
August 23, 2022
Wellbeing Corporate Update in a Letter from the CEO to its Shareholders
August 18, 2022
Wellbeing Digital Sciences Inc. Changes Year-End
August 11, 2022
Wellbeing Subsidiary KGK Science Enters Into Research Contract With Halucenex for Phase II Clinical Trial
July 20, 2022
Wellbeing Digital Sciences Announces the Appointment of Natalie Dolphin as VP of Marketing and Investment Relations
June 21, 2022
Wellbeing subsidiary KGK Science Announces Positive Clinical Trial Results of GJ 191 (JointAlive®) Supplementation in treating OA
June 17, 2022
Wellbeing Digital Sciences Announces Q3 Financial Results and Provides Corporate Update
June 16, 2022
Wellbeing Digital Sciences Announces the Appointment of Terry Zimaro as Chief Financial Officer of the Company
June 15, 2022
Wellbeing subsidiary KGK Science and the International Probiotics Association (“IPA”) applauds FDA’s Commitment to Release NDI Draft Guidance Documents in the Near Future
June 9, 2022
Wellbeing Digital Sciences’ Dr. Corey Hilmas Invited to Participate as a Regulatory Panelist at Probiota Americas Event
June 1, 2022
Wellbeing Digital Sciences Announces Resignation of Chief Financial Officer
May 27, 2022
Wellbeing Digital Sciences Becomes a Founding Sponsor of the Women in Psychedelics Network
May 10, 2022
Wellbeing Digital Sciences Welcomes Dr. Michael Ho as New Medical Director of MindScape Clinic in Houston
May 3, 2022
Wellbeing Digital Sciences Subsidiary IRP Health Approved as Part of Coveted Chronic Pain Centre of Excellence for Canadian Veterans Network
April 28, 2022
Wellbeing Digital Sciences Forms Special Committee to Explore Advances in Digital Therapeutics for Mental Health
April 25, 2022
Wellbeing Digital Sciences Signs MOU with Pathway Health Regarding the Potential Sale of Certain Assets
April 21, 2022
Wellbeing Digital Sciences Provides Commercial and Corporate Updates for KGK Science
April 19, 2022
Wellbeing Digital Sciences’ New CEO Unveils Evolved Competitive Strategy
April 14, 2022
Wellbeing Digital Sciences Welcomes Najla Guthrie as Chief Executive Officer
April 4, 2022
Wellbeing Digital Sciences Announces Restructuring of Security-Based Compensation
March 28, 2022
Wellbeing Digital Sciences’ Subsidiary KGK Science Completes Clinical Study for Shakeology® that Validates Weight Loss Benefits
March 22, 2022
Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study
March 21, 2022
Wellbeing Digital Sciences Reports Financial Results for the Second Fiscal Quarter of 2022
March 18, 2022
Wellbeing Digital Sciences Appoints Najla Guthrie as Chief Executive Officer
March 7, 2022